Molecular mimicry and cancer vaccine development

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Cancer immunotherapies depend on identifying tumor antigens for potent anti-tumor immune responses.
• Tumor-associated antigens (TAAs) are widely used for off-the-shelf cancer vaccines but can trigger tolerance or autoimmunity.
• TAAs are self-epitopes highly expressed on tumor cells but also presented on normal cells.

Purpose of the Study:

• To explore the potential of non-self-antigens from microorganisms (MoAs) as a strategy to enhance cancer immunotherapy.
• To overcome the limitations associated with traditional tumor-associated antigens (TAAs).

Main Methods:

• Investigating the use of analogue peptides with improved antigenicity and immunogenicity.
• Evaluating the potential of microbial-derived antigens (MoAs) to elicit cross-reactive T cell responses.

Main Results:

• Analogue peptides can be designed to improve antigenicity and immunogenicity.
• Microorganism-derived antigens (MoAs) show potential for eliciting cross-reactive T cell responses against tumors.

Conclusions:

• Microorganism-derived antigens (MoAs) represent a promising alternative to TAAs for cancer immunotherapy.
• Developing analogue peptides from MoAs can overcome TAA-related limitations like immunological tolerance and autoimmunity.